EMA/472121/2016

European Medicines Agency decision

P/0222/2016

of 12 August 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral for Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence (GSK2696274), (EMEA-001765-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0222/2016

of 12 August 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral for Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence (GSK2696274), (EMEA-001765-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by GlaxoSmithKline Trading Services Limited on 4 September 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 June 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence (GSK2696274), dispersion for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence (GSK2696274), dispersion for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to GlaxoSmithKline Trading Services Limited, Currabinny County Cork, 999937 – Carrigaline, Ireland.

EMA/PDCO/740439/2015
London, 24 June 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-001765-PIP02-15

Scope of the application

Active substance(s):

Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence (GSK2696274)

Condition(s):

Treatment of metachromatic leukodystrophy (MLD)

Pharmaceutical form(s):

Dispersion for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

GlaxoSmithKline Trading Services Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, GlaxoSmithKline Trading Services Limited submitted for agreement to the European Medicines Agency on 4 September 2015 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 13 October 2015.

Supplementary information was provided by the applicant on 24 March 2016. The applicant proposed modifications to the paediatric investigation plan and requested a deferral.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition

Treatment of metachromatic leukodystrophy (MLD)

2.1.1. Indication(s) targeted by the PIP

Treatment of presymptomatic Late Infantile (LI), and presymptomatic or early symptomatic Early Juvenile (EJ) and Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Dispersion for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of a cryopreserved dispersion for infusion formulation
Non-clinical studies	1	**Study 2** Study in As2-/- mice transplanted with bone marrow Lin- transduced with ARSA LV (GSK3485860; the murine equivalent of GSK2696274), to investigate the potential toxicity and tumorigenicity of GSK2696274.
Clinical studies	2	**Study 3** Open label, non-randomised, single centre, externally controlled trial to evaluate safety and efficacy of a single infusion of GSK2696274 in patients with Late Infantile (LI) and Early Juvenile (EJ) Metachromatic Leukodystrophy (MLD). **Study 4** Open label, non-randomised, externally controlled trial to evaluate safety and efficacy of a single infusion of GSK2696274 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD).

Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By May 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes